Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)

BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn’s disease (CD) in Korea. This study aimed to identify the preferences of Kor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Soo, Kim, Kyeong Ok, Jang, Byung Ik, Lee, Chang Kyun, Kim, Hyo Jong, Lee, Kang-Moon, Kim, You Sun, Eun, Chang Soo, Jung, Sung-Ae, Yang, Suk-Kyun, Lee, Jun, Kim, Tae-Oh, Jung, Yunho, Seo, Geom Seog, Yoon, Soon Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849692/
https://www.ncbi.nlm.nih.gov/pubmed/26347512
http://dx.doi.org/10.5009/gnl15126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849692/
https://www.ncbi.nlm.nih.gov/pubmed/26347512
http://dx.doi.org/10.5009/gnl15126

Ejemplares similares